Ameriprise sets aside $40M for private placement claims

Amount equals about 10% of total client losses on Reg D notes later deemed fraudulent by the SEC
APR 07, 2011
Ameriprise Financial Inc. said late today it was setting aside $40 million in legal reserves for class actions and legal claims arising from the sale of allegedly bogus private placements by its independent broker-dealer subsidiary, Securities America Inc. The reserves relate to sales of Medical Capital Holdings Inc. and Provident Royalties LLC. “With respect to potential resolution of such actions and claims subsequent to year-end, the company has recognized an additional provision of approximately $40 million in legal reserves,” Ameriprise said in its annual report. The amount is about 10% of the total that clients have lost in the two series of investments, Ameriprise said. “Approximately $400 million of Medical Capital and Provident Shale investments made by (Securities America) clients are outstanding and currently in default,” the company said. Just this month, a federal judge in Dallas put a halt to all arbitration claims relating to Securities America clients buying Medical Capital and Provident investments. That move was made so a preliminary class action settlement could be heard in the U.S. District Court for the Northern District of Texas. As part of Judge W. Royal Furgeson Jr.'s restraining order, Securities America agreed to contribute about $21 million to the pot of money available to investors. A preliminary approval hearing for that settlement has been set for March 18. A spokesman for Ameriprise did not immediately return a call seeking comment on this story. But plaintiffs' attorneys who represent individual investors who purchased the private placements say they will strongly oppose any class action settlement that prevents their clients from suing Securities America in private arbitration through the Financial Industry Regulatory Authority Inc. In 2009, the Securities and Exchange Commission charged both Medical Capital and Provident Royalties with fraud. Dozens of independent broker-dealers sold the high-risk products, with some closing down because of the costs arising from crippling litigation.

Latest News

The 2025 InvestmentNews Awards Excellence Awardees revealed
The 2025 InvestmentNews Awards Excellence Awardees revealed

From outstanding individuals to innovative organizations, find out who made the final shortlist for top honors at the IN awards, now in its second year.

Top RIA Cresset warns of 'inevitable' recession amid tariff uncertainty
Top RIA Cresset warns of 'inevitable' recession amid tariff uncertainty

Cresset's Susie Cranston is expecting an economic recession, but says her $65 billion RIA sees "great opportunity" to keep investing in a down market.

Edward Jones joins the crowd to sell more alternative investments
Edward Jones joins the crowd to sell more alternative investments

“There’s a big pull to alternative investments right now because of volatility of the stock market,” Kevin Gannon, CEO of Robert A. Stanger & Co., said.

Record RIA M&A activity marks strong start to 2025
Record RIA M&A activity marks strong start to 2025

Sellers shift focus: It's not about succession anymore.

IB+ Data Hub offers strategic edge for U.S. wealth advisors and RIAs advising business clients
IB+ Data Hub offers strategic edge for U.S. wealth advisors and RIAs advising business clients

Platform being adopted by independent-minded advisors who see insurance as a core pillar of their business.

SPONSORED Compliance in real time: Technology's expanding role in RIA oversight

RIAs face rising regulatory pressure in 2025. Forward-looking firms are responding with embedded technology, not more paperwork.

SPONSORED Advisory firms confront crossroads amid historic wealth transfer

As inheritances are set to reshape client portfolios and next-gen heirs demand digital-first experiences, firms are retooling their wealth tech stacks and succession models in real time.